Industry Experts

Xingfeng is currently SVP, Head of Biology and Translational Sciences at GV20 Therapeutics, a clinical stage, AI and cancer genomics-driven biotherapy company. Prior to joining GV20, he was Executive Director, Head of Cancer Immunology and Pharmacology at H3biomedicine, where he led the company’s discovery and translational biology group focused on cancer immunotherapy and antibody-drug conjugates. In his earlier career, he has also held roles of increasing responsibilities at Eisai oncology business unit. Xingfeng earned his doctorate in 2002 and completed his postdoctoral training at Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, California.